nodes	percent_of_prediction	percent_of_DWPC	metapath
Nateglinide—Potassium Channel Antagonists—Repaglinide—type 2 diabetes mellitus	0.338	1	CiPCiCtD
Nateglinide—Ramipril—type 2 diabetes mellitus	0.171	1	CrCtD
Nateglinide—ABCC8—type 2 diabetes mellitus	0.052	0.415	CbGaD
Nateglinide—KCNJ11—type 2 diabetes mellitus	0.0366	0.292	CbGaD
Nateglinide—PPARG—type 2 diabetes mellitus	0.0203	0.162	CbGaD
Nateglinide—Mitiglinide—Ramipril—type 2 diabetes mellitus	0.0178	0.169	CrCrCtD
Nateglinide—Spirapril—Ramipril—type 2 diabetes mellitus	0.0154	0.146	CrCrCtD
Nateglinide—Cilazapril—Ramipril—type 2 diabetes mellitus	0.0154	0.146	CrCrCtD
Nateglinide—Lisinopril—Ramipril—type 2 diabetes mellitus	0.0154	0.146	CrCrCtD
Nateglinide—Enalapril—Ramipril—type 2 diabetes mellitus	0.0145	0.137	CrCrCtD
Nateglinide—Trandolapril—Ramipril—type 2 diabetes mellitus	0.0145	0.137	CrCrCtD
Nateglinide—Aspartame—Ramipril—type 2 diabetes mellitus	0.0122	0.116	CrCrCtD
Nateglinide—ABCC8—Tolazamide—type 2 diabetes mellitus	0.0108	0.0554	CbGbCtD
Nateglinide—ABCC8—Glimepiride—type 2 diabetes mellitus	0.0096	0.0493	CbGbCtD
Nateglinide—KCNJ11—Tolazamide—type 2 diabetes mellitus	0.00931	0.0478	CbGbCtD
Nateglinide—PPARG—Glipizide—type 2 diabetes mellitus	0.00878	0.0451	CbGbCtD
Nateglinide—ABCC8—Glipizide—type 2 diabetes mellitus	0.00878	0.0451	CbGbCtD
Nateglinide—CYP3A4—type 2 diabetes mellitus	0.00875	0.0698	CbGaD
Nateglinide—KCNJ11—Glimepiride—type 2 diabetes mellitus	0.00829	0.0426	CbGbCtD
Nateglinide—ABCC8—Gliclazide—type 2 diabetes mellitus	0.00816	0.042	CbGbCtD
Nateglinide—PPARG—Repaglinide—type 2 diabetes mellitus	0.00767	0.0394	CbGbCtD
Nateglinide—ABCC8—Repaglinide—type 2 diabetes mellitus	0.00767	0.0394	CbGbCtD
Nateglinide—ALB—type 2 diabetes mellitus	0.00763	0.0609	CbGaD
Nateglinide—KCNJ11—Glipizide—type 2 diabetes mellitus	0.00759	0.039	CbGbCtD
Nateglinide—KCNJ11—Gliclazide—type 2 diabetes mellitus	0.00705	0.0363	CbGbCtD
Nateglinide—PPARG—Pioglitazone—type 2 diabetes mellitus	0.00694	0.0357	CbGbCtD
Nateglinide—ABCC8—Chlorpropamide—type 2 diabetes mellitus	0.00694	0.0357	CbGbCtD
Nateglinide—KCNJ11—Repaglinide—type 2 diabetes mellitus	0.00663	0.0341	CbGbCtD
Nateglinide—PPARG—Rosiglitazone—type 2 diabetes mellitus	0.0064	0.0329	CbGbCtD
Nateglinide—ABCC8—Tolbutamide—type 2 diabetes mellitus	0.00618	0.0318	CbGbCtD
Nateglinide—KCNJ11—Chlorpropamide—type 2 diabetes mellitus	0.006	0.0308	CbGbCtD
Nateglinide—KCNJ11—Tolbutamide—type 2 diabetes mellitus	0.00534	0.0275	CbGbCtD
Nateglinide—ABCC8—Glyburide—type 2 diabetes mellitus	0.00355	0.0183	CbGbCtD
Nateglinide—SLC15A2—Chlorpropamide—type 2 diabetes mellitus	0.00323	0.0166	CbGbCtD
Nateglinide—KCNJ11—Glyburide—type 2 diabetes mellitus	0.00307	0.0158	CbGbCtD
Nateglinide—SLC15A2—Tolbutamide—type 2 diabetes mellitus	0.00288	0.0148	CbGbCtD
Nateglinide—SLC15A1—Chlorpropamide—type 2 diabetes mellitus	0.00278	0.0143	CbGbCtD
Nateglinide—SLC15A2—Ramipril—type 2 diabetes mellitus	0.00257	0.0132	CbGbCtD
Nateglinide—SLC15A1—Tolbutamide—type 2 diabetes mellitus	0.00248	0.0128	CbGbCtD
Nateglinide—SLC15A1—Ramipril—type 2 diabetes mellitus	0.00221	0.0114	CbGbCtD
Nateglinide—PTGS1—Pioglitazone—type 2 diabetes mellitus	0.00175	0.00899	CbGbCtD
Nateglinide—PTGS1—Chlorpropamide—type 2 diabetes mellitus	0.00175	0.00899	CbGbCtD
Nateglinide—SLC15A2—Glyburide—type 2 diabetes mellitus	0.00165	0.0085	CbGbCtD
Nateglinide—PTGS1—Rosiglitazone—type 2 diabetes mellitus	0.00161	0.0083	CbGbCtD
Nateglinide—ALB—Gliclazide—type 2 diabetes mellitus	0.00154	0.0079	CbGbCtD
Nateglinide—SLC22A6—Chlorpropamide—type 2 diabetes mellitus	0.00153	0.00788	CbGbCtD
Nateglinide—ALB—Repaglinide—type 2 diabetes mellitus	0.00144	0.00742	CbGbCtD
Nateglinide—SLC15A1—Glyburide—type 2 diabetes mellitus	0.00142	0.00732	CbGbCtD
Nateglinide—SLC22A6—Tolbutamide—type 2 diabetes mellitus	0.00137	0.00703	CbGbCtD
Nateglinide—PTGS1—Irbesartan—type 2 diabetes mellitus	0.00127	0.00653	CbGbCtD
Nateglinide—ALB—Rosiglitazone—type 2 diabetes mellitus	0.00121	0.0062	CbGbCtD
Nateglinide—ALB—Valsartan—type 2 diabetes mellitus	0.00106	0.00547	CbGbCtD
Nateglinide—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.000974	0.00501	CbGbCtD
Nateglinide—CYP2C9—Glipizide—type 2 diabetes mellitus	0.00089	0.00458	CbGbCtD
Nateglinide—ABCC8—penis—type 2 diabetes mellitus	0.000863	0.0938	CbGeAlD
Nateglinide—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.000828	0.00426	CbGbCtD
Nateglinide—SLC22A6—Glyburide—type 2 diabetes mellitus	0.000785	0.00404	CbGbCtD
Nateglinide—SLC22A6—Losartan—type 2 diabetes mellitus	0.000718	0.00369	CbGbCtD
Nateglinide—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.000704	0.00362	CbGbCtD
Nateglinide—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.000704	0.00362	CbGbCtD
Nateglinide—PPARG—brown adipose tissue—type 2 diabetes mellitus	0.000692	0.0752	CbGeAlD
Nateglinide—ALB—Glyburide—type 2 diabetes mellitus	0.000668	0.00344	CbGbCtD
Nateglinide—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.00065	0.00334	CbGbCtD
Nateglinide—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.000644	0.00331	CbGbCtD
Nateglinide—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.000635	0.00327	CbGbCtD
Nateglinide—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.000627	0.00323	CbGbCtD
Nateglinide—ALB—Losartan—type 2 diabetes mellitus	0.000611	0.00314	CbGbCtD
Nateglinide—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.000594	0.00305	CbGbCtD
Nateglinide—CYP2C9—Valsartan—type 2 diabetes mellitus	0.000574	0.00295	CbGbCtD
Nateglinide—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.000566	0.00291	CbGbCtD
Nateglinide—PPARG—leg—type 2 diabetes mellitus	0.000557	0.0605	CbGeAlD
Nateglinide—CYP3A4—Glipizide—type 2 diabetes mellitus	0.000518	0.00266	CbGbCtD
Nateglinide—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.000511	0.00263	CbGbCtD
Nateglinide—PPARG—hindlimb—type 2 diabetes mellitus	0.000497	0.0541	CbGeAlD
Nateglinide—CYP3A5—Losartan—type 2 diabetes mellitus	0.000491	0.00253	CbGbCtD
Nateglinide—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.000468	0.0024	CbGbCtD
Nateglinide—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.000453	0.00233	CbGbCtD
Nateglinide—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.000409	0.0021	CbGbCtD
Nateglinide—CYP2C9—Glyburide—type 2 diabetes mellitus	0.00036	0.00185	CbGbCtD
Nateglinide—CYP2C9—Losartan—type 2 diabetes mellitus	0.00033	0.00169	CbGbCtD
Nateglinide—PPARG—artery—type 2 diabetes mellitus	0.000305	0.0331	CbGeAlD
Nateglinide—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.000297	0.00153	CbGbCtD
Nateglinide—CYP3A4—Orlistat—type 2 diabetes mellitus	0.000297	0.00153	CbGbCtD
Nateglinide—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.000281	0.00145	CbGbCtD
Nateglinide—PPARG—endothelium—type 2 diabetes mellitus	0.000257	0.028	CbGeAlD
Nateglinide—UGT1A9—kidney—type 2 diabetes mellitus	0.000211	0.0229	CbGeAlD
Nateglinide—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00021	0.00108	CbGbCtD
Nateglinide—KCNJ11—islet of Langerhans—type 2 diabetes mellitus	0.000208	0.0226	CbGeAlD
Nateglinide—ABCC8—islet of Langerhans—type 2 diabetes mellitus	0.000192	0.0209	CbGeAlD
Nateglinide—CYP3A4—Losartan—type 2 diabetes mellitus	0.000192	0.000985	CbGbCtD
Nateglinide—Amphetamine—CARTPT—type 2 diabetes mellitus	0.000179	0.195	CrCbGaD
Nateglinide—SLC22A6—nephron tubule—type 2 diabetes mellitus	0.000177	0.0193	CbGeAlD
Nateglinide—CYP3A7-CYP3A51P—nephron tubule—type 2 diabetes mellitus	0.00017	0.0184	CbGeAlD
Nateglinide—PTGS1—artery—type 2 diabetes mellitus	0.000163	0.0177	CbGeAlD
Nateglinide—SLC22A6—cortex of kidney—type 2 diabetes mellitus	0.000152	0.0165	CbGeAlD
Nateglinide—KCNJ11—cardiovascular system—type 2 diabetes mellitus	0.000151	0.0164	CbGeAlD
Nateglinide—Mitiglinide—ABCC8—type 2 diabetes mellitus	0.00015	0.164	CrCbGaD
Nateglinide—SLC16A1—retina—type 2 diabetes mellitus	0.000149	0.0162	CbGeAlD
Nateglinide—SLC15A1—nephron tubule—type 2 diabetes mellitus	0.000148	0.0161	CbGeAlD
Nateglinide—PPARG—islet of Langerhans—type 2 diabetes mellitus	0.000146	0.0159	CbGeAlD
Nateglinide—KCNJ11—pancreas—type 2 diabetes mellitus	0.000146	0.0159	CbGeAlD
Nateglinide—CYP3A7-CYP3A51P—cortex of kidney—type 2 diabetes mellitus	0.000145	0.0158	CbGeAlD
Nateglinide—ABCC8—cardiovascular system—type 2 diabetes mellitus	0.000139	0.0151	CbGeAlD
Nateglinide—PTGS1—endothelium—type 2 diabetes mellitus	0.000138	0.015	CbGeAlD
Nateglinide—ABCC8—kidney—type 2 diabetes mellitus	0.000136	0.0148	CbGeAlD
Nateglinide—ABCC8—pancreas—type 2 diabetes mellitus	0.000135	0.0147	CbGeAlD
Nateglinide—UGT1A9—liver—type 2 diabetes mellitus	0.000133	0.0145	CbGeAlD
Nateglinide—SLC15A1—kidney—type 2 diabetes mellitus	0.00013	0.0141	CbGeAlD
Nateglinide—SLC16A1—cardiovascular system—type 2 diabetes mellitus	0.000126	0.0137	CbGeAlD
Nateglinide—SLC16A1—kidney—type 2 diabetes mellitus	0.000124	0.0134	CbGeAlD
Nateglinide—SLC16A1—adipose tissue—type 2 diabetes mellitus	0.000111	0.0121	CbGeAlD
Nateglinide—CYP3A7—liver—type 2 diabetes mellitus	0.000111	0.012	CbGeAlD
Nateglinide—ABCC4—nephron tubule—type 2 diabetes mellitus	0.000107	0.0116	CbGeAlD
Nateglinide—Mitiglinide—KCNJ11—type 2 diabetes mellitus	0.000106	0.115	CrCbGaD
Nateglinide—PPARG—cardiovascular system—type 2 diabetes mellitus	0.000106	0.0115	CbGeAlD
Nateglinide—PPARG—kidney—type 2 diabetes mellitus	0.000104	0.0113	CbGeAlD
Nateglinide—PPARG—pancreas—type 2 diabetes mellitus	0.000103	0.0112	CbGeAlD
Nateglinide—SLC15A2—retina—type 2 diabetes mellitus	9.8e-05	0.0107	CbGeAlD
Nateglinide—CYP3A7-CYP3A51P—liver—type 2 diabetes mellitus	9.42e-05	0.0102	CbGeAlD
Nateglinide—ABCC4—kidney—type 2 diabetes mellitus	9.41e-05	0.0102	CbGeAlD
Nateglinide—ABCC4—pancreas—type 2 diabetes mellitus	9.35e-05	0.0102	CbGeAlD
Nateglinide—PPARG—adipose tissue—type 2 diabetes mellitus	9.34e-05	0.0102	CbGeAlD
Nateglinide—SLC15A2—nephron tubule—type 2 diabetes mellitus	9.23e-05	0.01	CbGeAlD
Nateglinide—ABCC4—cortex of kidney—type 2 diabetes mellitus	9.16e-05	0.00997	CbGeAlD
Nateglinide—CYP3A5—islet of Langerhans—type 2 diabetes mellitus	8.71e-05	0.00948	CbGeAlD
Nateglinide—ABCC4—adipose tissue—type 2 diabetes mellitus	8.48e-05	0.00922	CbGeAlD
Nateglinide—SLC15A1—liver—type 2 diabetes mellitus	8.2e-05	0.00892	CbGeAlD
Nateglinide—SLC15A2—kidney—type 2 diabetes mellitus	8.11e-05	0.00882	CbGeAlD
Nateglinide—SLC15A2—cortex of kidney—type 2 diabetes mellitus	7.9e-05	0.00859	CbGeAlD
Nateglinide—SLC16A1—liver—type 2 diabetes mellitus	7.81e-05	0.00849	CbGeAlD
Nateglinide—CYP3A5—nephron tubule—type 2 diabetes mellitus	7.02e-05	0.00763	CbGeAlD
Nateglinide—ORM1—liver—type 2 diabetes mellitus	7.01e-05	0.00762	CbGeAlD
Nateglinide—PPARG—liver—type 2 diabetes mellitus	6.55e-05	0.00712	CbGeAlD
Nateglinide—CYP2C9—cardiovascular system—type 2 diabetes mellitus	6.2e-05	0.00674	CbGeAlD
Nateglinide—CYP3A5—kidney—type 2 diabetes mellitus	6.17e-05	0.0067	CbGeAlD
Nateglinide—Spirapril—ACE—type 2 diabetes mellitus	6.15e-05	0.067	CrCbGaD
Nateglinide—ALB—liver—type 2 diabetes mellitus	6.14e-05	0.00668	CbGeAlD
Nateglinide—CYP3A5—pancreas—type 2 diabetes mellitus	6.13e-05	0.00666	CbGeAlD
Nateglinide—CYP3A5—cortex of kidney—type 2 diabetes mellitus	6.01e-05	0.00653	CbGeAlD
Nateglinide—ABCC4—liver—type 2 diabetes mellitus	5.95e-05	0.00647	CbGeAlD
Nateglinide—Mitiglinide—PPARG—type 2 diabetes mellitus	5.87e-05	0.064	CrCbGaD
Nateglinide—Nausea—Acarbose—type 2 diabetes mellitus	5.75e-05	0.0018	CcSEcCtD
Nateglinide—Hepatobiliary disease—Metformin—type 2 diabetes mellitus	5.73e-05	0.0018	CcSEcCtD
Nateglinide—Pruritus—Repaglinide—type 2 diabetes mellitus	5.72e-05	0.00179	CcSEcCtD
Nateglinide—PTGS1—cardiovascular system—type 2 diabetes mellitus	5.66e-05	0.00616	CbGeAlD
Nateglinide—Malnutrition—Gliclazide—type 2 diabetes mellitus	5.66e-05	0.00177	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Losartan—type 2 diabetes mellitus	5.61e-05	0.00176	CcSEcCtD
Nateglinide—Jaundice—Irbesartan—type 2 diabetes mellitus	5.57e-05	0.00175	CcSEcCtD
Nateglinide—CYP3A5—adipose tissue—type 2 diabetes mellitus	5.56e-05	0.00604	CbGeAlD
Nateglinide—PTGS1—kidney—type 2 diabetes mellitus	5.54e-05	0.00602	CbGeAlD
Nateglinide—Gastrointestinal disorder—Pioglitazone—type 2 diabetes mellitus	5.53e-05	0.00173	CcSEcCtD
Nateglinide—Diarrhoea—Repaglinide—type 2 diabetes mellitus	5.53e-05	0.00173	CcSEcCtD
Nateglinide—Fatigue—Pioglitazone—type 2 diabetes mellitus	5.52e-05	0.00173	CcSEcCtD
Nateglinide—Dyspepsia—Glimepiride—type 2 diabetes mellitus	5.49e-05	0.00172	CcSEcCtD
Nateglinide—Lisinopril—ACE—type 2 diabetes mellitus	5.48e-05	0.0597	CrCbGaD
Nateglinide—Cilazapril—ACE—type 2 diabetes mellitus	5.48e-05	0.0597	CrCbGaD
Nateglinide—Asthenia—Rosiglitazone—type 2 diabetes mellitus	5.48e-05	0.00172	CcSEcCtD
Nateglinide—Back pain—Gliclazide—type 2 diabetes mellitus	5.47e-05	0.00172	CcSEcCtD
Nateglinide—Dyspepsia—Sitagliptin—type 2 diabetes mellitus	5.47e-05	0.00172	CcSEcCtD
Nateglinide—Gastrointestinal pain—Glipizide—type 2 diabetes mellitus	5.47e-05	0.00171	CcSEcCtD
Nateglinide—Hepatobiliary disease—Irbesartan—type 2 diabetes mellitus	5.41e-05	0.0017	CcSEcCtD
Nateglinide—Pruritus—Rosiglitazone—type 2 diabetes mellitus	5.4e-05	0.00169	CcSEcCtD
Nateglinide—Immune system disorder—Valsartan—type 2 diabetes mellitus	5.39e-05	0.00169	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Glimepiride—type 2 diabetes mellitus	5.38e-05	0.00169	CcSEcCtD
Nateglinide—Fatigue—Glimepiride—type 2 diabetes mellitus	5.38e-05	0.00169	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Sitagliptin—type 2 diabetes mellitus	5.37e-05	0.00168	CcSEcCtD
Nateglinide—Fatigue—Sitagliptin—type 2 diabetes mellitus	5.36e-05	0.00168	CcSEcCtD
Nateglinide—Oedema peripheral—Metformin—type 2 diabetes mellitus	5.36e-05	0.00168	CcSEcCtD
Nateglinide—Immune system disorder—Orlistat—type 2 diabetes mellitus	5.33e-05	0.00167	CcSEcCtD
Nateglinide—Urticaria—Glipizide—type 2 diabetes mellitus	5.31e-05	0.00166	CcSEcCtD
Nateglinide—Ramipril—ACE—type 2 diabetes mellitus	5.31e-05	0.0578	CrCbGaD
Nateglinide—Trandolapril—ACE—type 2 diabetes mellitus	5.31e-05	0.0578	CrCbGaD
Nateglinide—Tremor—Gliclazide—type 2 diabetes mellitus	5.3e-05	0.00166	CcSEcCtD
Nateglinide—Abdominal pain—Glipizide—type 2 diabetes mellitus	5.28e-05	0.00166	CcSEcCtD
Nateglinide—Neuropathy peripheral—Losartan—type 2 diabetes mellitus	5.27e-05	0.00165	CcSEcCtD
Nateglinide—Jaundice—Losartan—type 2 diabetes mellitus	5.25e-05	0.00164	CcSEcCtD
Nateglinide—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	5.22e-05	0.00164	CcSEcCtD
Nateglinide—Malnutrition—Valsartan—type 2 diabetes mellitus	5.2e-05	0.00163	CcSEcCtD
Nateglinide—Influenza—Ramipril—type 2 diabetes mellitus	5.17e-05	0.00162	CcSEcCtD
Nateglinide—Sweating—Losartan—type 2 diabetes mellitus	5.16e-05	0.00162	CcSEcCtD
Nateglinide—Malnutrition—Orlistat—type 2 diabetes mellitus	5.14e-05	0.00161	CcSEcCtD
Nateglinide—Vomiting—Repaglinide—type 2 diabetes mellitus	5.14e-05	0.00161	CcSEcCtD
Nateglinide—Gastrointestinal pain—Glimepiride—type 2 diabetes mellitus	5.1e-05	0.0016	CcSEcCtD
Nateglinide—Rash—Repaglinide—type 2 diabetes mellitus	5.09e-05	0.0016	CcSEcCtD
Nateglinide—Dermatitis—Repaglinide—type 2 diabetes mellitus	5.09e-05	0.0016	CcSEcCtD
Nateglinide—Urticaria—Pioglitazone—type 2 diabetes mellitus	5.09e-05	0.00159	CcSEcCtD
Nateglinide—Gastrointestinal pain—Sitagliptin—type 2 diabetes mellitus	5.08e-05	0.00159	CcSEcCtD
Nateglinide—Oedema peripheral—Irbesartan—type 2 diabetes mellitus	5.06e-05	0.00159	CcSEcCtD
Nateglinide—Dizziness—Rosiglitazone—type 2 diabetes mellitus	5.05e-05	0.00158	CcSEcCtD
Nateglinide—Sweating increased—Ramipril—type 2 diabetes mellitus	5.04e-05	0.00158	CcSEcCtD
Nateglinide—Back pain—Valsartan—type 2 diabetes mellitus	5.03e-05	0.00158	CcSEcCtD
Nateglinide—Palpitations—Gliclazide—type 2 diabetes mellitus	5e-05	0.00157	CcSEcCtD
Nateglinide—PTGS1—adipose tissue—type 2 diabetes mellitus	4.99e-05	0.00543	CbGeAlD
Nateglinide—Bronchitis—Ramipril—type 2 diabetes mellitus	4.98e-05	0.00156	CcSEcCtD
Nateglinide—Hyperhidrosis—Glyburide—type 2 diabetes mellitus	4.97e-05	0.00156	CcSEcCtD
Nateglinide—Back pain—Orlistat—type 2 diabetes mellitus	4.97e-05	0.00156	CcSEcCtD
Nateglinide—Urticaria—Glimepiride—type 2 diabetes mellitus	4.95e-05	0.00155	CcSEcCtD
Nateglinide—Dyspepsia—Bromocriptine—type 2 diabetes mellitus	4.95e-05	0.00155	CcSEcCtD
Nateglinide—Urticaria—Sitagliptin—type 2 diabetes mellitus	4.94e-05	0.00155	CcSEcCtD
Nateglinide—Cough—Gliclazide—type 2 diabetes mellitus	4.94e-05	0.00155	CcSEcCtD
Nateglinide—Abdominal pain—Glimepiride—type 2 diabetes mellitus	4.93e-05	0.00155	CcSEcCtD
Nateglinide—Hypersensitivity—Glipizide—type 2 diabetes mellitus	4.92e-05	0.00154	CcSEcCtD
Nateglinide—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	4.91e-05	0.00154	CcSEcCtD
Nateglinide—Immune system disorder—Metformin—type 2 diabetes mellitus	4.91e-05	0.00154	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	4.86e-05	0.00152	CcSEcCtD
Nateglinide—Fatigue—Bromocriptine—type 2 diabetes mellitus	4.85e-05	0.00152	CcSEcCtD
Nateglinide—Rash—Rosiglitazone—type 2 diabetes mellitus	4.81e-05	0.00151	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Ramipril—type 2 diabetes mellitus	4.81e-05	0.00151	CcSEcCtD
Nateglinide—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	4.81e-05	0.00151	CcSEcCtD
Nateglinide—Nausea—Repaglinide—type 2 diabetes mellitus	4.8e-05	0.0015	CcSEcCtD
Nateglinide—Asthenia—Glipizide—type 2 diabetes mellitus	4.8e-05	0.0015	CcSEcCtD
Nateglinide—Malnutrition—Metformin—type 2 diabetes mellitus	4.73e-05	0.00148	CcSEcCtD
Nateglinide—Pruritus—Glipizide—type 2 diabetes mellitus	4.73e-05	0.00148	CcSEcCtD
Nateglinide—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	4.72e-05	0.00148	CcSEcCtD
Nateglinide—Immune system disorder—Irbesartan—type 2 diabetes mellitus	4.64e-05	0.00145	CcSEcCtD
Nateglinide—CYP3A4—kidney—type 2 diabetes mellitus	4.63e-05	0.00503	CbGeAlD
Nateglinide—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	4.6e-05	0.00144	CcSEcCtD
Nateglinide—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	4.6e-05	0.00144	CcSEcCtD
Nateglinide—Palpitations—Valsartan—type 2 diabetes mellitus	4.59e-05	0.00144	CcSEcCtD
Nateglinide—Asthenia—Pioglitazone—type 2 diabetes mellitus	4.59e-05	0.00144	CcSEcCtD
Nateglinide—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	4.58e-05	0.00144	CcSEcCtD
Nateglinide—Diarrhoea—Glipizide—type 2 diabetes mellitus	4.57e-05	0.00143	CcSEcCtD
Nateglinide—Erythema multiforme—Losartan—type 2 diabetes mellitus	4.57e-05	0.00143	CcSEcCtD
Nateglinide—CYP2D6—kidney—type 2 diabetes mellitus	4.55e-05	0.00495	CbGeAlD
Nateglinide—Palpitations—Orlistat—type 2 diabetes mellitus	4.54e-05	0.00142	CcSEcCtD
Nateglinide—Cough—Valsartan—type 2 diabetes mellitus	4.54e-05	0.00142	CcSEcCtD
Nateglinide—Nausea—Rosiglitazone—type 2 diabetes mellitus	4.53e-05	0.00142	CcSEcCtD
Nateglinide—Dyspepsia—Glyburide—type 2 diabetes mellitus	4.53e-05	0.00142	CcSEcCtD
Nateglinide—Neuropathy peripheral—Ramipril—type 2 diabetes mellitus	4.52e-05	0.00142	CcSEcCtD
Nateglinide—Jaundice—Ramipril—type 2 diabetes mellitus	4.5e-05	0.00141	CcSEcCtD
Nateglinide—Cough—Orlistat—type 2 diabetes mellitus	4.48e-05	0.00141	CcSEcCtD
Nateglinide—Asthenia—Glimepiride—type 2 diabetes mellitus	4.47e-05	0.0014	CcSEcCtD
Nateglinide—Urticaria—Bromocriptine—type 2 diabetes mellitus	4.47e-05	0.0014	CcSEcCtD
Nateglinide—Malnutrition—Irbesartan—type 2 diabetes mellitus	4.47e-05	0.0014	CcSEcCtD
Nateglinide—Hyperhidrosis—Gliclazide—type 2 diabetes mellitus	4.47e-05	0.0014	CcSEcCtD
Nateglinide—Asthenia—Sitagliptin—type 2 diabetes mellitus	4.46e-05	0.0014	CcSEcCtD
Nateglinide—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	4.45e-05	0.00139	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	4.44e-05	0.00139	CcSEcCtD
Nateglinide—Tremor—Metformin—type 2 diabetes mellitus	4.44e-05	0.00139	CcSEcCtD
Nateglinide—Sweating—Ramipril—type 2 diabetes mellitus	4.42e-05	0.00139	CcSEcCtD
Nateglinide—Dizziness—Glipizide—type 2 diabetes mellitus	4.42e-05	0.00139	CcSEcCtD
Nateglinide—Pruritus—Glimepiride—type 2 diabetes mellitus	4.41e-05	0.00138	CcSEcCtD
Nateglinide—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	4.38e-05	0.00137	CcSEcCtD
Nateglinide—Hepatobiliary disease—Ramipril—type 2 diabetes mellitus	4.36e-05	0.00137	CcSEcCtD
Nateglinide—Diarrhoea—Glimepiride—type 2 diabetes mellitus	4.27e-05	0.00134	CcSEcCtD
Nateglinide—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	4.25e-05	0.00133	CcSEcCtD
Nateglinide—Vomiting—Glipizide—type 2 diabetes mellitus	4.25e-05	0.00133	CcSEcCtD
Nateglinide—Dizziness—Pioglitazone—type 2 diabetes mellitus	4.23e-05	0.00133	CcSEcCtD
Nateglinide—Rash—Glipizide—type 2 diabetes mellitus	4.21e-05	0.00132	CcSEcCtD
Nateglinide—Dermatitis—Glipizide—type 2 diabetes mellitus	4.21e-05	0.00132	CcSEcCtD
Nateglinide—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	4.21e-05	0.00132	CcSEcCtD
Nateglinide—Tremor—Irbesartan—type 2 diabetes mellitus	4.19e-05	0.00131	CcSEcCtD
Nateglinide—Palpitations—Metformin—type 2 diabetes mellitus	4.18e-05	0.00131	CcSEcCtD
Nateglinide—Dizziness—Glimepiride—type 2 diabetes mellitus	4.12e-05	0.00129	CcSEcCtD
Nateglinide—Dizziness—Sitagliptin—type 2 diabetes mellitus	4.11e-05	0.00129	CcSEcCtD
Nateglinide—Urticaria—Glyburide—type 2 diabetes mellitus	4.09e-05	0.00128	CcSEcCtD
Nateglinide—Oedema peripheral—Ramipril—type 2 diabetes mellitus	4.08e-05	0.00128	CcSEcCtD
Nateglinide—Back pain—Losartan—type 2 diabetes mellitus	4.07e-05	0.00128	CcSEcCtD
Nateglinide—Abdominal pain—Glyburide—type 2 diabetes mellitus	4.07e-05	0.00127	CcSEcCtD
Nateglinide—Dyspepsia—Gliclazide—type 2 diabetes mellitus	4.07e-05	0.00127	CcSEcCtD
Nateglinide—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	4.05e-05	0.00127	CcSEcCtD
Nateglinide—Asthenia—Bromocriptine—type 2 diabetes mellitus	4.04e-05	0.00127	CcSEcCtD
Nateglinide—Enalapril—ACE—type 2 diabetes mellitus	4.02e-05	0.0438	CrCbGaD
Nateglinide—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	3.99e-05	0.00125	CcSEcCtD
Nateglinide—Fatigue—Gliclazide—type 2 diabetes mellitus	3.98e-05	0.00125	CcSEcCtD
Nateglinide—Nausea—Glipizide—type 2 diabetes mellitus	3.97e-05	0.00124	CcSEcCtD
Nateglinide—Vomiting—Glimepiride—type 2 diabetes mellitus	3.97e-05	0.00124	CcSEcCtD
Nateglinide—Vomiting—Sitagliptin—type 2 diabetes mellitus	3.95e-05	0.00124	CcSEcCtD
Nateglinide—Tremor—Losartan—type 2 diabetes mellitus	3.94e-05	0.00124	CcSEcCtD
Nateglinide—Rash—Glimepiride—type 2 diabetes mellitus	3.93e-05	0.00123	CcSEcCtD
Nateglinide—Dermatitis—Glimepiride—type 2 diabetes mellitus	3.93e-05	0.00123	CcSEcCtD
Nateglinide—Rash—Sitagliptin—type 2 diabetes mellitus	3.92e-05	0.00123	CcSEcCtD
Nateglinide—Dermatitis—Sitagliptin—type 2 diabetes mellitus	3.92e-05	0.00123	CcSEcCtD
Nateglinide—Erythema multiforme—Ramipril—type 2 diabetes mellitus	3.92e-05	0.00123	CcSEcCtD
Nateglinide—Cough—Irbesartan—type 2 diabetes mellitus	3.9e-05	0.00122	CcSEcCtD
Nateglinide—CYP3A5—liver—type 2 diabetes mellitus	3.9e-05	0.00424	CbGeAlD
Nateglinide—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	3.85e-05	0.00121	CcSEcCtD
Nateglinide—CYP2C9—liver—type 2 diabetes mellitus	3.84e-05	0.00417	CbGeAlD
Nateglinide—Bortezomib—CYP1A2—type 2 diabetes mellitus	3.8e-05	0.0413	CrCbGaD
Nateglinide—Hypersensitivity—Glyburide—type 2 diabetes mellitus	3.79e-05	0.00119	CcSEcCtD
Nateglinide—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	3.78e-05	0.00118	CcSEcCtD
Nateglinide—Immune system disorder—Ramipril—type 2 diabetes mellitus	3.74e-05	0.00117	CcSEcCtD
Nateglinide—Hyperhidrosis—Metformin—type 2 diabetes mellitus	3.74e-05	0.00117	CcSEcCtD
Nateglinide—Dyspepsia—Valsartan—type 2 diabetes mellitus	3.74e-05	0.00117	CcSEcCtD
Nateglinide—Dizziness—Bromocriptine—type 2 diabetes mellitus	3.72e-05	0.00117	CcSEcCtD
Nateglinide—Palpitations—Losartan—type 2 diabetes mellitus	3.72e-05	0.00117	CcSEcCtD
Nateglinide—Nausea—Glimepiride—type 2 diabetes mellitus	3.7e-05	0.00116	CcSEcCtD
Nateglinide—Nausea—Sitagliptin—type 2 diabetes mellitus	3.69e-05	0.00116	CcSEcCtD
Nateglinide—Dyspepsia—Orlistat—type 2 diabetes mellitus	3.69e-05	0.00116	CcSEcCtD
Nateglinide—Asthenia—Glyburide—type 2 diabetes mellitus	3.69e-05	0.00116	CcSEcCtD
Nateglinide—Cough—Losartan—type 2 diabetes mellitus	3.67e-05	0.00115	CcSEcCtD
Nateglinide—Urticaria—Gliclazide—type 2 diabetes mellitus	3.67e-05	0.00115	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	3.66e-05	0.00115	CcSEcCtD
Nateglinide—Fatigue—Valsartan—type 2 diabetes mellitus	3.66e-05	0.00115	CcSEcCtD
Nateglinide—Abdominal pain—Gliclazide—type 2 diabetes mellitus	3.65e-05	0.00114	CcSEcCtD
Nateglinide—Pruritus—Glyburide—type 2 diabetes mellitus	3.64e-05	0.00114	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	3.62e-05	0.00114	CcSEcCtD
Nateglinide—Fatigue—Orlistat—type 2 diabetes mellitus	3.62e-05	0.00113	CcSEcCtD
Nateglinide—Malnutrition—Ramipril—type 2 diabetes mellitus	3.61e-05	0.00113	CcSEcCtD
Nateglinide—Vomiting—Bromocriptine—type 2 diabetes mellitus	3.58e-05	0.00112	CcSEcCtD
Nateglinide—Rash—Bromocriptine—type 2 diabetes mellitus	3.55e-05	0.00111	CcSEcCtD
Nateglinide—Dermatitis—Bromocriptine—type 2 diabetes mellitus	3.54e-05	0.00111	CcSEcCtD
Nateglinide—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	3.53e-05	0.00111	CcSEcCtD
Nateglinide—Diarrhoea—Glyburide—type 2 diabetes mellitus	3.52e-05	0.0011	CcSEcCtD
Nateglinide—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	3.47e-05	0.00109	CcSEcCtD
Nateglinide—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	3.43e-05	0.00108	CcSEcCtD
Nateglinide—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	3.4e-05	0.00107	CcSEcCtD
Nateglinide—Dyspepsia—Metformin—type 2 diabetes mellitus	3.4e-05	0.00107	CcSEcCtD
Nateglinide—Tremor—Ramipril—type 2 diabetes mellitus	3.38e-05	0.00106	CcSEcCtD
Nateglinide—Urticaria—Valsartan—type 2 diabetes mellitus	3.37e-05	0.00106	CcSEcCtD
Nateglinide—Abdominal pain—Valsartan—type 2 diabetes mellitus	3.35e-05	0.00105	CcSEcCtD
Nateglinide—Nausea—Bromocriptine—type 2 diabetes mellitus	3.34e-05	0.00105	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	3.34e-05	0.00105	CcSEcCtD
Nateglinide—Fatigue—Metformin—type 2 diabetes mellitus	3.33e-05	0.00104	CcSEcCtD
Nateglinide—Urticaria—Orlistat—type 2 diabetes mellitus	3.33e-05	0.00104	CcSEcCtD
Nateglinide—Hyperhidrosis—Losartan—type 2 diabetes mellitus	3.32e-05	0.00104	CcSEcCtD
Nateglinide—Abdominal pain—Orlistat—type 2 diabetes mellitus	3.31e-05	0.00104	CcSEcCtD
Nateglinide—Asthenia—Gliclazide—type 2 diabetes mellitus	3.31e-05	0.00104	CcSEcCtD
Nateglinide—Vomiting—Glyburide—type 2 diabetes mellitus	3.27e-05	0.00103	CcSEcCtD
Nateglinide—Pruritus—Gliclazide—type 2 diabetes mellitus	3.27e-05	0.00102	CcSEcCtD
Nateglinide—Rash—Glyburide—type 2 diabetes mellitus	3.24e-05	0.00102	CcSEcCtD
Nateglinide—Dermatitis—Glyburide—type 2 diabetes mellitus	3.24e-05	0.00102	CcSEcCtD
Nateglinide—Dyspepsia—Irbesartan—type 2 diabetes mellitus	3.21e-05	0.00101	CcSEcCtD
Nateglinide—Palpitations—Ramipril—type 2 diabetes mellitus	3.19e-05	0.000999	CcSEcCtD
Nateglinide—Diarrhoea—Gliclazide—type 2 diabetes mellitus	3.16e-05	0.000991	CcSEcCtD
Nateglinide—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	3.16e-05	0.000991	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	3.15e-05	0.000987	CcSEcCtD
Nateglinide—Cough—Ramipril—type 2 diabetes mellitus	3.15e-05	0.000987	CcSEcCtD
Nateglinide—Fatigue—Irbesartan—type 2 diabetes mellitus	3.14e-05	0.000986	CcSEcCtD
Nateglinide—Hypersensitivity—Valsartan—type 2 diabetes mellitus	3.13e-05	0.00098	CcSEcCtD
Nateglinide—Hypersensitivity—Orlistat—type 2 diabetes mellitus	3.09e-05	0.000969	CcSEcCtD
Nateglinide—Urticaria—Metformin—type 2 diabetes mellitus	3.07e-05	0.000963	CcSEcCtD
Nateglinide—Nausea—Glyburide—type 2 diabetes mellitus	3.06e-05	0.000958	CcSEcCtD
Nateglinide—Abdominal pain—Metformin—type 2 diabetes mellitus	3.05e-05	0.000958	CcSEcCtD
Nateglinide—Dizziness—Gliclazide—type 2 diabetes mellitus	3.05e-05	0.000958	CcSEcCtD
Nateglinide—Asthenia—Valsartan—type 2 diabetes mellitus	3.04e-05	0.000955	CcSEcCtD
Nateglinide—Dyspepsia—Losartan—type 2 diabetes mellitus	3.02e-05	0.000947	CcSEcCtD
Nateglinide—Asthenia—Orlistat—type 2 diabetes mellitus	3.01e-05	0.000943	CcSEcCtD
Nateglinide—Pruritus—Valsartan—type 2 diabetes mellitus	3e-05	0.000941	CcSEcCtD
Nateglinide—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	2.98e-05	0.000935	CcSEcCtD
Nateglinide—Pruritus—Orlistat—type 2 diabetes mellitus	2.97e-05	0.00093	CcSEcCtD
Nateglinide—Fatigue—Losartan—type 2 diabetes mellitus	2.96e-05	0.000928	CcSEcCtD
Nateglinide—Vomiting—Gliclazide—type 2 diabetes mellitus	2.94e-05	0.000921	CcSEcCtD
Nateglinide—CYP3A4—liver—type 2 diabetes mellitus	2.92e-05	0.00318	CbGeAlD
Nateglinide—Rash—Gliclazide—type 2 diabetes mellitus	2.91e-05	0.000913	CcSEcCtD
Nateglinide—Dermatitis—Gliclazide—type 2 diabetes mellitus	2.91e-05	0.000912	CcSEcCtD
Nateglinide—Diarrhoea—Valsartan—type 2 diabetes mellitus	2.9e-05	0.00091	CcSEcCtD
Nateglinide—Urticaria—Irbesartan—type 2 diabetes mellitus	2.9e-05	0.000908	CcSEcCtD
Nateglinide—Abdominal pain—Irbesartan—type 2 diabetes mellitus	2.88e-05	0.000904	CcSEcCtD
Nateglinide—CYP2D6—liver—type 2 diabetes mellitus	2.88e-05	0.00313	CbGeAlD
Nateglinide—Diarrhoea—Orlistat—type 2 diabetes mellitus	2.87e-05	0.0009	CcSEcCtD
Nateglinide—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	2.84e-05	0.000892	CcSEcCtD
Nateglinide—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	2.81e-05	0.00088	CcSEcCtD
Nateglinide—Dizziness—Valsartan—type 2 diabetes mellitus	2.81e-05	0.00088	CcSEcCtD
Nateglinide—Dizziness—Orlistat—type 2 diabetes mellitus	2.77e-05	0.000869	CcSEcCtD
Nateglinide—Asthenia—Metformin—type 2 diabetes mellitus	2.77e-05	0.000869	CcSEcCtD
Nateglinide—Nausea—Gliclazide—type 2 diabetes mellitus	2.74e-05	0.00086	CcSEcCtD
Nateglinide—Pruritus—Metformin—type 2 diabetes mellitus	2.73e-05	0.000857	CcSEcCtD
Nateglinide—Urticaria—Losartan—type 2 diabetes mellitus	2.73e-05	0.000855	CcSEcCtD
Nateglinide—Abdominal pain—Losartan—type 2 diabetes mellitus	2.71e-05	0.000851	CcSEcCtD
Nateglinide—Vomiting—Valsartan—type 2 diabetes mellitus	2.7e-05	0.000846	CcSEcCtD
Nateglinide—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	2.69e-05	0.000842	CcSEcCtD
Nateglinide—Rash—Valsartan—type 2 diabetes mellitus	2.68e-05	0.000839	CcSEcCtD
Nateglinide—Dermatitis—Valsartan—type 2 diabetes mellitus	2.67e-05	0.000838	CcSEcCtD
Nateglinide—Vomiting—Orlistat—type 2 diabetes mellitus	2.67e-05	0.000836	CcSEcCtD
Nateglinide—Diarrhoea—Metformin—type 2 diabetes mellitus	2.64e-05	0.000829	CcSEcCtD
Nateglinide—Rash—Orlistat—type 2 diabetes mellitus	2.64e-05	0.000829	CcSEcCtD
Nateglinide—Dermatitis—Orlistat—type 2 diabetes mellitus	2.64e-05	0.000828	CcSEcCtD
Nateglinide—Asthenia—Irbesartan—type 2 diabetes mellitus	2.62e-05	0.00082	CcSEcCtD
Nateglinide—Dyspepsia—Ramipril—type 2 diabetes mellitus	2.59e-05	0.000812	CcSEcCtD
Nateglinide—Pruritus—Irbesartan—type 2 diabetes mellitus	2.58e-05	0.000809	CcSEcCtD
Nateglinide—Dizziness—Metformin—type 2 diabetes mellitus	2.56e-05	0.000801	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	2.54e-05	0.000797	CcSEcCtD
Nateglinide—Fatigue—Ramipril—type 2 diabetes mellitus	2.54e-05	0.000795	CcSEcCtD
Nateglinide—Hypersensitivity—Losartan—type 2 diabetes mellitus	2.53e-05	0.000793	CcSEcCtD
Nateglinide—Nausea—Valsartan—type 2 diabetes mellitus	2.52e-05	0.00079	CcSEcCtD
Nateglinide—Bortezomib—CYP3A4—type 2 diabetes mellitus	2.51e-05	0.0274	CrCbGaD
Nateglinide—Diarrhoea—Irbesartan—type 2 diabetes mellitus	2.5e-05	0.000782	CcSEcCtD
Nateglinide—Nausea—Orlistat—type 2 diabetes mellitus	2.49e-05	0.000781	CcSEcCtD
Nateglinide—Asthenia—Losartan—type 2 diabetes mellitus	2.46e-05	0.000772	CcSEcCtD
Nateglinide—Vomiting—Metformin—type 2 diabetes mellitus	2.46e-05	0.00077	CcSEcCtD
Nateglinide—Rash—Metformin—type 2 diabetes mellitus	2.44e-05	0.000764	CcSEcCtD
Nateglinide—Dermatitis—Metformin—type 2 diabetes mellitus	2.43e-05	0.000763	CcSEcCtD
Nateglinide—Pruritus—Losartan—type 2 diabetes mellitus	2.43e-05	0.000761	CcSEcCtD
Nateglinide—Methamphetamine—ADRA2A—type 2 diabetes mellitus	2.42e-05	0.0263	CrCbGaD
Nateglinide—Dizziness—Irbesartan—type 2 diabetes mellitus	2.41e-05	0.000756	CcSEcCtD
Nateglinide—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	2.41e-05	0.000754	CcSEcCtD
Nateglinide—Diarrhoea—Losartan—type 2 diabetes mellitus	2.35e-05	0.000736	CcSEcCtD
Nateglinide—Urticaria—Ramipril—type 2 diabetes mellitus	2.34e-05	0.000733	CcSEcCtD
Nateglinide—Abdominal pain—Ramipril—type 2 diabetes mellitus	2.33e-05	0.000729	CcSEcCtD
Nateglinide—Vomiting—Irbesartan—type 2 diabetes mellitus	2.32e-05	0.000727	CcSEcCtD
Nateglinide—Rash—Irbesartan—type 2 diabetes mellitus	2.3e-05	0.000721	CcSEcCtD
Nateglinide—Dermatitis—Irbesartan—type 2 diabetes mellitus	2.3e-05	0.00072	CcSEcCtD
Nateglinide—Nausea—Metformin—type 2 diabetes mellitus	2.3e-05	0.00072	CcSEcCtD
Nateglinide—Dizziness—Losartan—type 2 diabetes mellitus	2.27e-05	0.000712	CcSEcCtD
Nateglinide—Vomiting—Losartan—type 2 diabetes mellitus	2.18e-05	0.000684	CcSEcCtD
Nateglinide—Hypersensitivity—Ramipril—type 2 diabetes mellitus	2.17e-05	0.00068	CcSEcCtD
Nateglinide—Nausea—Irbesartan—type 2 diabetes mellitus	2.17e-05	0.000679	CcSEcCtD
Nateglinide—Rash—Losartan—type 2 diabetes mellitus	2.16e-05	0.000678	CcSEcCtD
Nateglinide—Dermatitis—Losartan—type 2 diabetes mellitus	2.16e-05	0.000678	CcSEcCtD
Nateglinide—Asthenia—Ramipril—type 2 diabetes mellitus	2.11e-05	0.000662	CcSEcCtD
Nateglinide—Pruritus—Ramipril—type 2 diabetes mellitus	2.08e-05	0.000653	CcSEcCtD
Nateglinide—Nausea—Losartan—type 2 diabetes mellitus	2.04e-05	0.000639	CcSEcCtD
Nateglinide—Diarrhoea—Ramipril—type 2 diabetes mellitus	2.01e-05	0.000631	CcSEcCtD
Nateglinide—Dizziness—Ramipril—type 2 diabetes mellitus	1.95e-05	0.00061	CcSEcCtD
Nateglinide—Enalapril—CYP3A4—type 2 diabetes mellitus	1.89e-05	0.0206	CrCbGaD
Nateglinide—Vomiting—Ramipril—type 2 diabetes mellitus	1.87e-05	0.000587	CcSEcCtD
Nateglinide—Rash—Ramipril—type 2 diabetes mellitus	1.86e-05	0.000582	CcSEcCtD
Nateglinide—Dermatitis—Ramipril—type 2 diabetes mellitus	1.85e-05	0.000581	CcSEcCtD
Nateglinide—Nausea—Ramipril—type 2 diabetes mellitus	1.75e-05	0.000548	CcSEcCtD
Nateglinide—PPARG—Metabolism—NOS3—type 2 diabetes mellitus	8.15e-07	3.45e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PIK3R1—type 2 diabetes mellitus	8.15e-07	3.45e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PPARG—type 2 diabetes mellitus	8.14e-07	3.45e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CPT1A—type 2 diabetes mellitus	8.1e-07	3.43e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—MTR—type 2 diabetes mellitus	8.1e-07	3.43e-05	CbGpPWpGaD
Nateglinide—ALB—Platelet activation, signaling and aggregation—AKT1—type 2 diabetes mellitus	8.06e-07	3.42e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—MTR—type 2 diabetes mellitus	8.03e-07	3.4e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CPT1A—type 2 diabetes mellitus	8.03e-07	3.4e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PPARA—type 2 diabetes mellitus	8.03e-07	3.4e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—AGT—type 2 diabetes mellitus	8.02e-07	3.4e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—INS—type 2 diabetes mellitus	7.98e-07	3.38e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—NAMPT—type 2 diabetes mellitus	7.95e-07	3.37e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	7.91e-07	3.35e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	7.91e-07	3.35e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—HBA1—type 2 diabetes mellitus	7.9e-07	3.35e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—LIPC—type 2 diabetes mellitus	7.9e-07	3.35e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GCK—type 2 diabetes mellitus	7.9e-07	3.35e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—CALM1—type 2 diabetes mellitus	7.89e-07	3.34e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—NAMPT—type 2 diabetes mellitus	7.88e-07	3.34e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—APOE—type 2 diabetes mellitus	7.86e-07	3.33e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CYP11A1—type 2 diabetes mellitus	7.85e-07	3.32e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CYP2E1—type 2 diabetes mellitus	7.85e-07	3.32e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	7.83e-07	3.32e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—HBA1—type 2 diabetes mellitus	7.83e-07	3.32e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—LIPC—type 2 diabetes mellitus	7.83e-07	3.32e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GCK—type 2 diabetes mellitus	7.83e-07	3.32e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYP11A1—type 2 diabetes mellitus	7.78e-07	3.3e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	7.78e-07	3.29e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—AGT—type 2 diabetes mellitus	7.77e-07	3.29e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—APOA1—type 2 diabetes mellitus	7.77e-07	3.29e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CYP1A2—type 2 diabetes mellitus	7.76e-07	3.29e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—SLC2A1—type 2 diabetes mellitus	7.76e-07	3.29e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—SLC9A1—type 2 diabetes mellitus	7.71e-07	3.27e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—CALM1—type 2 diabetes mellitus	7.64e-07	3.24e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	7.64e-07	3.24e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	7.64e-07	3.24e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	7.64e-07	3.24e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—SLC9A1—type 2 diabetes mellitus	7.64e-07	3.24e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CETP—type 2 diabetes mellitus	7.62e-07	3.23e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—APOE—type 2 diabetes mellitus	7.62e-07	3.23e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CYP3A4—type 2 diabetes mellitus	7.57e-07	3.21e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CETP—type 2 diabetes mellitus	7.55e-07	3.2e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—APOA1—type 2 diabetes mellitus	7.53e-07	3.19e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	7.53e-07	3.19e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PTGS2—type 2 diabetes mellitus	7.45e-07	3.16e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—GNB3—type 2 diabetes mellitus	7.44e-07	3.15e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PPARGC1A—type 2 diabetes mellitus	7.44e-07	3.15e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GCG—type 2 diabetes mellitus	7.44e-07	3.15e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—SLC2A4—type 2 diabetes mellitus	7.44e-07	3.15e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—HMOX1—type 2 diabetes mellitus	7.41e-07	3.14e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—ALB—type 2 diabetes mellitus	7.32e-07	3.1e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CAT—type 2 diabetes mellitus	7.31e-07	3.1e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	7.19e-07	3.04e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—APOB—type 2 diabetes mellitus	7.1e-07	3.01e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—SNAP25—type 2 diabetes mellitus	7.08e-07	3e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PSMD6—type 2 diabetes mellitus	7.08e-07	3e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—SREBF1—type 2 diabetes mellitus	7.08e-07	3e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	7.04e-07	2.98e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—SNAP25—type 2 diabetes mellitus	7.02e-07	2.97e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PSMD6—type 2 diabetes mellitus	7.02e-07	2.97e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—SREBF1—type 2 diabetes mellitus	7.02e-07	2.97e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—NOS3—type 2 diabetes mellitus	7e-07	2.97e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PIK3R1—type 2 diabetes mellitus	7e-07	2.97e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	6.95e-07	2.95e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—GSTM1—type 2 diabetes mellitus	6.9e-07	2.93e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CTGF—type 2 diabetes mellitus	6.89e-07	2.92e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	6.89e-07	2.92e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PPARG—type 2 diabetes mellitus	6.85e-07	2.9e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—HMGCR—type 2 diabetes mellitus	6.83e-07	2.89e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—LPL—type 2 diabetes mellitus	6.78e-07	2.87e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	6.74e-07	2.86e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	6.74e-07	2.85e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	6.73e-07	2.85e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—INS—type 2 diabetes mellitus	6.71e-07	2.84e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—SRC—type 2 diabetes mellitus	6.69e-07	2.83e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ADRA2A—type 2 diabetes mellitus	6.69e-07	2.83e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PPARG—type 2 diabetes mellitus	6.64e-07	2.81e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—ADCY5—type 2 diabetes mellitus	6.64e-07	2.81e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—GPX1—type 2 diabetes mellitus	6.61e-07	2.8e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—VEGFA—type 2 diabetes mellitus	6.51e-07	2.76e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—INS—type 2 diabetes mellitus	6.51e-07	2.76e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	6.5e-07	2.75e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	6.5e-07	2.75e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	6.5e-07	2.75e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	6.5e-07	2.75e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	6.48e-07	2.74e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CD36—type 2 diabetes mellitus	6.44e-07	2.73e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYP2E1—type 2 diabetes mellitus	6.42e-07	2.72e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GNB3—type 2 diabetes mellitus	6.41e-07	2.72e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PPARGC1A—type 2 diabetes mellitus	6.41e-07	2.72e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	6.41e-07	2.71e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	6.41e-07	2.71e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PTGS2—type 2 diabetes mellitus	6.4e-07	2.71e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—HMOX1—type 2 diabetes mellitus	6.38e-07	2.7e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PPP2CA—type 2 diabetes mellitus	6.36e-07	2.69e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—SLC2A1—type 2 diabetes mellitus	6.35e-07	2.69e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYP1A2—type 2 diabetes mellitus	6.35e-07	2.69e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CAT—type 2 diabetes mellitus	6.3e-07	2.67e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	6.25e-07	2.65e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	6.23e-07	2.64e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYP3A4—type 2 diabetes mellitus	6.19e-07	2.62e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	6.16e-07	2.61e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—ALB—type 2 diabetes mellitus	6.16e-07	2.61e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	6.14e-07	2.6e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	6.14e-07	2.6e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—APOB—type 2 diabetes mellitus	6.11e-07	2.59e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—MTHFR—type 2 diabetes mellitus	6.1e-07	2.59e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—SLC2A4—type 2 diabetes mellitus	6.09e-07	2.58e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GCG—type 2 diabetes mellitus	6.09e-07	2.58e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PPARA—type 2 diabetes mellitus	5.99e-07	2.54e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—TGFB1—type 2 diabetes mellitus	5.98e-07	2.53e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—ALB—type 2 diabetes mellitus	5.97e-07	2.53e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GSTM1—type 2 diabetes mellitus	5.95e-07	2.52e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PIK3R1—type 2 diabetes mellitus	5.89e-07	2.49e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—NOS3—type 2 diabetes mellitus	5.89e-07	2.49e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—LPL—type 2 diabetes mellitus	5.84e-07	2.47e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—AGT—type 2 diabetes mellitus	5.8e-07	2.46e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	5.79e-07	2.45e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—ADCY5—type 2 diabetes mellitus	5.71e-07	2.42e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PIK3R1—type 2 diabetes mellitus	5.71e-07	2.42e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—NOS3—type 2 diabetes mellitus	5.71e-07	2.42e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CALM1—type 2 diabetes mellitus	5.7e-07	2.42e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GPX1—type 2 diabetes mellitus	5.69e-07	2.41e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—APOE—type 2 diabetes mellitus	5.68e-07	2.41e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—APOA1—type 2 diabetes mellitus	5.62e-07	2.38e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CD36—type 2 diabetes mellitus	5.55e-07	2.35e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PPP2CA—type 2 diabetes mellitus	5.48e-07	2.32e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	5.41e-07	2.29e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PTGS2—type 2 diabetes mellitus	5.39e-07	2.28e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	5.3e-07	2.24e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	5.3e-07	2.24e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.29e-07	2.24e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	5.29e-07	2.24e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	5.27e-07	2.23e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—MTHFR—type 2 diabetes mellitus	5.26e-07	2.23e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	5.25e-07	2.22e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.25e-07	2.22e-05	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—AKT1—type 2 diabetes mellitus	5.23e-07	2.21e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	5.22e-07	2.21e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PTGS2—type 2 diabetes mellitus	5.22e-07	2.21e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	5.2e-07	2.2e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	5.2e-07	2.2e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	5.16e-07	2.19e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	5.16e-07	2.19e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	5.16e-07	2.19e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PPARA—type 2 diabetes mellitus	5.16e-07	2.18e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	5.15e-07	2.18e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	5.13e-07	2.17e-05	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—AKT1—type 2 diabetes mellitus	5.07e-07	2.15e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	5.05e-07	2.14e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	5.04e-07	2.13e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	5e-07	2.12e-05	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—AKT1—type 2 diabetes mellitus	4.99e-07	2.12e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—AGT—type 2 diabetes mellitus	4.99e-07	2.12e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	4.98e-07	2.11e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PPARG—type 2 diabetes mellitus	4.95e-07	2.1e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CALM1—type 2 diabetes mellitus	4.91e-07	2.08e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	4.91e-07	2.08e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—APOE—type 2 diabetes mellitus	4.89e-07	2.07e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	4.87e-07	2.06e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—INS—type 2 diabetes mellitus	4.85e-07	2.06e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—APOA1—type 2 diabetes mellitus	4.84e-07	2.05e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	4.82e-07	2.04e-05	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—AKT1—type 2 diabetes mellitus	4.82e-07	2.04e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	4.78e-07	2.02e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	4.72e-07	2e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	4.7e-07	1.99e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	4.68e-07	1.98e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	4.66e-07	1.97e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	4.63e-07	1.96e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	4.63e-07	1.96e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	4.63e-07	1.96e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	4.58e-07	1.94e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	4.55e-07	1.93e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	4.54e-07	1.92e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	4.52e-07	1.92e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	4.51e-07	1.91e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	4.48e-07	1.9e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—ALB—type 2 diabetes mellitus	4.45e-07	1.88e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	4.41e-07	1.87e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	4.34e-07	1.84e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	4.3e-07	1.82e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PPARG—type 2 diabetes mellitus	4.26e-07	1.81e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	4.26e-07	1.8e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PIK3R1—type 2 diabetes mellitus	4.26e-07	1.8e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—NOS3—type 2 diabetes mellitus	4.26e-07	1.8e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	4.24e-07	1.79e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	4.22e-07	1.79e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	4.19e-07	1.77e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	4.19e-07	1.77e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—INS—type 2 diabetes mellitus	4.18e-07	1.77e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—AKT1—type 2 diabetes mellitus	4.16e-07	1.76e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	4.12e-07	1.75e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	4.09e-07	1.73e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	4.05e-07	1.72e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	4.04e-07	1.71e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	4.02e-07	1.7e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	4.02e-07	1.7e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	4.02e-07	1.7e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	4e-07	1.7e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	3.99e-07	1.69e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	3.96e-07	1.68e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	3.89e-07	1.65e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—AKT1—type 2 diabetes mellitus	3.75e-07	1.59e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PIK3R1—type 2 diabetes mellitus	3.67e-07	1.55e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—NOS3—type 2 diabetes mellitus	3.67e-07	1.55e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	3.52e-07	1.49e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	3.49e-07	1.48e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.46e-07	1.47e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	3.46e-07	1.47e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	3.45e-07	1.46e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	3.45e-07	1.46e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	3.42e-07	1.45e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	3.4e-07	1.44e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PTGS2—type 2 diabetes mellitus	3.35e-07	1.42e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	3.3e-07	1.4e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—AKT1—type 2 diabetes mellitus	3.22e-07	1.36e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	3.21e-07	1.36e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	3.16e-07	1.34e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	3.15e-07	1.33e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	3.14e-07	1.33e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	3.08e-07	1.31e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	3.07e-07	1.3e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	3.03e-07	1.28e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	3.03e-07	1.28e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	3e-07	1.27e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	3e-07	1.27e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	2.99e-07	1.27e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	2.96e-07	1.25e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	2.84e-07	1.2e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	2.78e-07	1.18e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	2.77e-07	1.17e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	2.74e-07	1.16e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—AKT1—type 2 diabetes mellitus	2.71e-07	1.15e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	2.7e-07	1.14e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	2.65e-07	1.12e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	2.64e-07	1.12e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—AKT1—type 2 diabetes mellitus	2.62e-07	1.11e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	2.61e-07	1.11e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	2.3e-07	9.75e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	2.26e-07	9.56e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	2.07e-07	8.76e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	1.98e-07	8.38e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	1.98e-07	8.38e-06	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	1.96e-07	8.29e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	1.81e-07	7.67e-06	CbGpPWpGaD
Nateglinide—ALB—Metabolism—AKT1—type 2 diabetes mellitus	1.68e-07	7.14e-06	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	1.39e-07	5.89e-06	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	1.38e-07	5.84e-06	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	9.1e-08	3.85e-06	CbGpPWpGaD
